Baxter aims to divide and conquer


US drugmaker Baxter International is spinning off its biopharmaceuticals business to create two independent companies.

The biopharma unit will include Baxter’s existing plasma- and recombinant protein-based drugs for haemophilia, along with treatments for other blood-related conditions. The company stated that it will look to add to its pipeline of treatments and diagnostics for bleeding disorders through collaborations and acquisitions.

The remaining ‘medical products’ outfit includes Baxter’s dialysis equipment, as well as intravenous drug delivery systems, anaesthetics and surgical equipment. That business will aim to grow by increasing its geographical reach and streamlining costs.


Related Content

Baxter to pay $4bn for dialysis firm

6 December 2012 Business

news image

Gambro makes products for hemodialysis and continuous renal replacement therapy

Nanoparticle divides to conquer

17 January 2011 News Archive

news image

Nanoparticle breaks up into smaller units once it reaches a tumour, allowing it to penetrate deeper and deliver treatment mor...

Most Commented

New antibiotic picked from nose bacteria

27 July 2016 Research

news image

Discovery suggests human microbiome may be an untapped source of antimicrobial compounds

Beyond element 118: the next row of the periodic table

29 January 2016 News and Analysis

news image

A technological leap may be called for to expand the number of elements in existence